Established Statin Use Reduces Mortality From Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis

*Emma Fitzgerald,1 Laurel Duquette,2 Matthew Williams1

1. Academic Department of Critical Care, Queen Alexandra Hospital and University of Portsmouth, Portsmouth, UK
2. University Hospitals Network, University of Toronto, Toronto, Ontario, Canada
*Correspondence to

Disclosure: The authors have declared no conflicts of interest.
Received: 24.11.14 Accepted: 27.02.15
Citation: EMJ Respir. 2015;3[1]:46-55.


Background: Statin therapy (ST) has been associated with improved outcomes from sepsis. Our objective was to systematically review the association between established ST and outcomes of patients with community-acquired pneumonia (CAP) that is severe enough to require hospitalisation.
Methods: Two meta-analyses were conducted following a search of articles published before 31st January 2013. After exclusions, seven studies were included to assess the effects of statins on 30-day mortality from CAP, and eight studies were included to assess the effects of statins on the development of CAP. Endpoints were a reduction in the risk of 30-day mortality or risk of developing CAP.
Results: A reduction in the risk of 30-day mortality from CAP was identified in patients established on ST (pooled odds ratio [OR]: 0.70, 95% confidence interval [CI]: 0.65-0.76; adjusted OR: 0.58, 95% CI: 0.47-0.69). The pooled OR for risk of developing CAP in patients with and without established ST was 1.01 (95% CI: 0.98-1.04).
Conclusion: There appears to be weak evidence to suggest a potential benefit of established ST. It is associated with a reduced risk of 30-day mortality in patients subsequently hospitalised with CAP. Further evidence is required, but ST could be considered as a means of reducing the risk of mortality from pneumonia.

Download (PDF, 161KB)

Comments are closed.